全文获取类型
收费全文 | 7984篇 |
免费 | 542篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 66篇 |
妇产科学 | 236篇 |
基础医学 | 1778篇 |
口腔科学 | 80篇 |
临床医学 | 479篇 |
内科学 | 918篇 |
皮肤病学 | 69篇 |
神经病学 | 528篇 |
特种医学 | 156篇 |
外科学 | 555篇 |
综合类 | 913篇 |
现状与发展 | 1篇 |
预防医学 | 1303篇 |
眼科学 | 45篇 |
药学 | 997篇 |
中国医学 | 168篇 |
肿瘤学 | 342篇 |
出版年
2024年 | 4篇 |
2023年 | 253篇 |
2022年 | 310篇 |
2021年 | 328篇 |
2020年 | 487篇 |
2019年 | 349篇 |
2018年 | 312篇 |
2017年 | 650篇 |
2016年 | 573篇 |
2015年 | 679篇 |
2014年 | 802篇 |
2013年 | 563篇 |
2012年 | 451篇 |
2011年 | 350篇 |
2010年 | 529篇 |
2009年 | 465篇 |
2008年 | 154篇 |
2007年 | 235篇 |
2006年 | 146篇 |
2005年 | 123篇 |
2004年 | 85篇 |
2003年 | 94篇 |
2002年 | 103篇 |
2001年 | 116篇 |
2000年 | 56篇 |
1999年 | 106篇 |
1998年 | 95篇 |
1997年 | 12篇 |
1996年 | 25篇 |
1995年 | 15篇 |
1994年 | 15篇 |
1993年 | 22篇 |
1992年 | 15篇 |
1991年 | 17篇 |
1990年 | 24篇 |
1989年 | 14篇 |
1988年 | 12篇 |
1987年 | 9篇 |
1986年 | 4篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 2篇 |
1970年 | 2篇 |
排序方式: 共有8650条查询结果,搜索用时 78 毫秒
51.
52.
53.
The mechanism of action of C-reactive protein (CRP) in protecting mice against lethal Streptococcus pneumoniae infection is unknown. The involvement of the phosphocholine (PCh)-binding property of CRP in its antipneumococcal function previously has been explored twice, with conflicting results. In this study, using three different intravenous sepsis mouse models, we investigated the role of the PCh-binding property of CRP by employing a CRP mutant incapable of binding to PCh. The ability of wild-type CRP to protect mice against infection was found to differ in the three models; the protective ability of wild-type CRP decreased when the severity of infection was increased, as determined by measuring mortality and bacteremia. In the first animal model, in which we used 25 μg of CRP and 107 CFU of pneumococci, both wild-type and mutant CRP protected mice against infection, suggesting that the protection was independent of the PCh-binding activity of CRP. In the second model, in which we used 25 μg of CRP and 5 × 107 CFU of pneumococci, mutant CRP was not protective while wild-type CRP was, suggesting that the protection was dependent on the PCh-binding activity of CRP. In the third model, in which we used 150 μg of CRP and 107 CFU of pneumococci, mutant CRP was as protective as wild-type CRP, again indicating that the protection was independent of the PCh-binding activity of CRP. We conclude that both PCh-dependent and PCh-independent mechanisms are involved in the CRP-mediated decrease in bacteremia and the resulting protection of mice against pneumococcal infection. 相似文献
54.
The new EU Tobacco Product Directive (TPD) prohibits tobacco products containing additives that are toxic in unburnt form or that increase overall toxicity of the product. This paper proposes a strategy to assess additive attributed toxicity in the context of the TPD. Literature was searched on toxicity testing strategies for regulatory purposes from tobacco industry and governmental institutes. Although mainly traditional in vivo testing strategies have been applied to assess toxicity of unburnt additives and increases in overall toxicity of tobacco products due to additives, in vitro tests combined with toxicogenomics and validated using biomarkers of exposure and disease are most promising in this respect. As such, tests are needed that are sensitive enough to assess additive attributed toxicity above the overall toxicity of tobacco products, which can associate assay outcomes to human risk and exposure. In conclusion, new, sensitive in vitro assays are needed to conclude whether comparable testing allows for assessment of small changes in overall toxicity attributed to additives. A more pragmatic approach for implementation on a short-term is mandated lowering of toxic emission components. Combined with risk assessment, this approach allows assessment of effectiveness of harm reduction strategies, including banning or reducing of additives. 相似文献
55.
《Vaccine》2016,34(33):3862-3866
The objective of the present study was to assess safety and efficacy of a new modified live-virus porcine reproductive and respiratory syndrome (PRRS) genotype 1 vaccine in pregnant sows at various stages of gestation under field conditions. A total of 505 sows and gilts were allocated to two treatment groups and maintained in separate facilities. Animals of group 1 were vaccinated with a commercial modified live genotype 1 PRRSV vaccine (control product, CP), while animals of group 2 were immunized with a new modified live genotype 1 PRRSV vaccine (investigational veterinary product, IVP) (ReproCyc® PRRS EU, Boehringer Ingelheim Vetmedica GmbH). Injection site reactions were noted to be significantly less frequent in the IVP group compared to the CP group for pain (p = 0.039), redness (p = 0.030), heat (p = 0.016) and swelling (p = 0.002). The mean total number of piglets alive at weaning did not differ significantly between both study groups (10.6 vs. 11.0, p = 0.375). However, pre-weaning mortality was significantly higher (p = 0.005) in piglets from the CP group (14.1% vs. 10.9%). Analyses of reproductive performance data for both groups did not result in statistically significant differences between CP group and IVP group for number of piglets alive (12.7 and 12.6, respectively), healthy live (11.9 and 11.8), weak (0.7 and 0.5), stillborn (1.0 and 0.8) and mummified piglets (0.3 and 0.2) per litter. No differences were detected between both groups for piglet birth weights, while body weights at weaning (7.2 kg vs. 6.6 kg, p = 0.026) and average daily gain (0.2445 kg vs. 0.2211 kg, p = 0.037) were significantly higher in piglets from the IVP group. In conclusion, the administration of a single dose of ReproCyc® PRRS EU to sows and gilts at various stages of gestation confirmed non-inferiority to a commercial PRRS vaccine regarding safety and efficacy parameters under field conditions. 相似文献
56.
57.
Ying Xu Nian-Zhang Zhang Meng Wang Hu Dong Sheng-Yong Feng Hui-Chen Guo Xing-Quan Zhu 《Parasitology research》2015,114(11):4195-4203
58.
Abie Awu Meng-yu Shao Meng-meng Liu Yan-xin Hu Zhuo-ming Qin Fu-lin Tian 《Avian pathology》2015,44(3):204-211
For over three decades, there has been a continuing panzootic caused by a virulent variant avian paramyxovirus type 1 strain, the so-called pigeon paramyxovirus type 1. It is found primarily in racing pigeons, but it has also spread to wild birds and poultry. In this study, two pigeon paramyxovirus type 1 strains, SD12 and BJ13, obtained from diseased pigeons in China, were characterized. Phylogenetic analysis based on complete sequences allowed characterization of both strains as genotype VI, class II. Further phylogenetic analysis of a 374-nucleotide section of the fusion gene showed that SD12 fell into lineage VIbii-d and BJ13 into VIbii-f. The deduced amino acid sequence of the cleavage site of the fusion protein confirmed that both isolates contained the virulent motif 112K/RRQKR↓F117 at the cleavage site. Nevertheless, the values of intracerebral pathogenicity indices showed the SD12 isolate to be a velogenic strain and BJ13 isolate to be a mesogenic strain. The SD12 isolate was further investigated via clinical observation, RNA detection, histopathology and viral serology in experimentally infected 3-week-old chickens. It showed a mild pathological phenotype in chickens, with viral replication restricted to a few tissues. The molecular mechanism for the SD12 isolate to have a virulent motif but low levels of virulence for chickens requires further study. 相似文献
59.
《Vaccine》2016,34(11):1370-1378
Tuberculosis (TB) is a serious disease around the world, and protein based subunit vaccine is supposed to be a kind of promising novel vaccine against it. However, there is no effective adjuvant available in clinic to activate cell-mediated immune responses which is required for TB subunit vaccine. Therefore, it is imperative to develop new adjuvant. Here we reported an adjuvant composed of dimethyl dioctadecylammonium (DDA), Poly I:C and cholesterol (DPC for short). DDA can form a kind of cationic liposome with the ability to deliver and present antigen and can induce Th1 type cell-mediated immune response. Poly I:C, a ligand of TLR3 receptor, could attenuate the pathologic reaction induced by following Mycobacterium tuberculosis challenge. Cholesterol, which could enhance rigidity of lipid bilayer, is added to DDA and Poly I:C to improve the stability of the adjuvant. The particle size and Zeta-potential of DPC were analyzed in vitro. Furthermore, DPC was mixed with a TB fusion protein ESAT6-Ag85B-MPT64(190-198)-Mtb8.4-Rv2626c (LT70) to construct a subunit vaccine. The subunit vaccine-induced immune responses and protective efficacy against M. tuberculosis H37Rv infection in C57BL/6 mice were investigated. The results showed that the DPC adjuvant with particle size of 400 nm and zeta potential of 40 mV was in good stability. LT70 in the adjuvant of DPC generated strong antigen-specific humoral and cell-mediated immunity, and induced long-term higher protective efficacy against M. tuberculosis infection (5.41 ± 0.38 log10 CFU) than traditional vaccine Bacillus Calmette–Guerin (BCG) (6.01 ± 0.33 log10 CFU) and PBS control (6.53 ± 0.26 log10 CFU) at 30 weeks post-vaccination. In conclusion, DPC would be a promising vaccine adjuvant with the ability to stimulate Th1 type cell-mediated immunity, and could be used in TB subunit vaccine. 相似文献
60.